Workforce strategy

The CRA-to-CTM Transition: How the Decisions You Own Change

Explore the shift from individual site findings to study-wide decisions, escalation and verification when moving from CRA to CTM.

By Lampgen Clinical Research

A research professional considers site folders and a wider study meeting, illustrating expanding decision responsibilities.
Conceptual editorial illustration; it does not depict an observed study procedure, actual patient data or a demonstrated treatment outcome.

3 min read · estimated

Sources
Site findingStudy-level response
Titles vary by organization; decision authority must be defined explicitly.

What the source reported

FDA’s ICH E6(R3) guidance emphasizes risk-proportionate approaches and clarifies sponsor and investigator responsibilities. [1] FDA’s monitoring guidance describes planning and communication of monitoring findings. [2] These sources provide a quality framework; they do not define a universal CRA-to-CTM promotion ladder or prescribe job titles. The career examples below are Lampgen’s interpretation of how responsibilities can develop.

What this means for trial teams

A strong CRA builds a dependable account of what is happening at a site. A CTM often has to determine whether observations across sites call for a coordinated study response. The difference is partly scale, but it also concerns dependencies, authority and the consequences of a decision. More meetings alone do not create more effective oversight.

Start with an illustrative laboratory issue. At one site, a collection misses the required processing window. The CRA examines the available records, follows the monitoring plan, documents the finding and routes questions to the appropriate study contacts. The immediate task is to make the event understandable and support an appropriate response within the role’s authority.

Now imagine similar issues appearing at several sites. The study team has a different question: are these separate local errors, or is something in training, courier arrangements, kit instructions or scheduling contributing to a repeated problem? The CTM can bring the relevant functions together, establish who owns the investigation and help coordinate the resulting plan. The hypothetical example does not establish its own root cause.

That transition requires careful language. An observation is what the records show. An interpretation is what may explain it. A recommendation is a proposed next step. A decision is an authorized choice. Keeping those distinctions visible helps teams act without overstating the evidence or bypassing medical, quality, regulatory or investigator responsibilities.

For CRAs preparing to move into management, build examples around decisions you helped improve. Explain the issue, the evidence available, its possible consequences and the people you engaged. Describe what happened afterward, including uncertainty or an outcome you could not verify. A well-supported account of one meaningful problem can be more useful than a long list of activities.

For hiring managers, use the same operational scenario at different levels. Ask a CRA candidate what they would verify at the site. Ask a CTM candidate how they would evaluate a cross-site pattern and coordinate a response. Then test what each would escalate and why. Clinical knowledge matters alongside awareness of role boundaries.

Tommy Lampley’s background across CRA, Lead CRA and study-management roles informs Lampgen’s perspective. His CV records work at ICON, PPD, Advenchen and BeiGene. That history is context, rather than proof of involvement in this illustrative scenario. Career paths differ, and sponsor work is one form of responsibility among several valuable clinical-research roles.

The practical impact is better role definition. A contractor can contribute faster when the assignment states the decisions they can make, the decisions they coordinate and the decisions they must escalate. For a CRA-to-CTM transition, prepare for that conversation before focusing on the next title.

Sources

  1. FDA — ICH E6(R3), final guidance, September 2025
  2. FDA — Risk-Based Monitoring Questions and Answers, April 2023

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?